Clinical Trial Update: Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels [Phase 2]

View source ↗

Summary

Phase 2 trial update on a monoclonal antibody targeting PCSK9 to lower LDL-C in adults not on lipid therapy; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• monoclonal antibody targeting PCSK9 (PCSK9 inhibitor)

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 2 | Status: COMPLETED | Results posted: 2015-10-05